Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia
To the Editor: Kelton et al. (Feb. 21 issue) 1 recommend fondaparinux for the management of heparin-induced thrombocytopenia in patients with normal renal function because of its ease of use and familiarity, but it has another advantage as well: cost. At our institution, 10 days of treatment with fo...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2013-06, Vol.368 (24), p.2333-2334 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2334 |
|---|---|
| container_issue | 24 |
| container_start_page | 2333 |
| container_title | The New England journal of medicine |
| container_volume | 368 |
| creator | Jenkins, Ian Humber, Doug Bhatt, Vijaya R Aryal, Madan R Armitage, James O |
| description | To the Editor:
Kelton et al. (Feb. 21 issue)
1
recommend fondaparinux for the management of heparin-induced thrombocytopenia in patients with normal renal function because of its ease of use and familiarity, but it has another advantage as well: cost. At our institution, 10 days of treatment with fondaparinux at a dose of 7.5 mg per day costs $400. A 10-day infusion of argatroban costs approximately $7,440, plus an estimated $800 in laboratory costs and the indirect cost of pharmacist supervision, which in sum costs at least $7,840 more than fondaparinux. The costs of different treatment options are particularly relevant when . . . |
| doi_str_mv | 10.1056/NEJMc1303640 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1367881852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1367881852</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-519ddf5c24eb80d61afec903603fddc12bba39af1997d497780ae4843ae46ef63</originalsourceid><addsrcrecordid>eNqN0T1PwzAQBmALgWgpbMwoEgwMBOzYceIFqaoKBZWylDly_EFTNXawk6H_HkMKQogBD-fhHr06-wA4RfAawZTeLKaPTwJhiCmBe2CIUoxjQiDdB0MIkzwmGcMDcOT9GoaDCDsEgwRnaZ6kaAhuF9asVMNdZaKxaSth-Wu34ab1kbYumvWt-MHITigZLVfO1qUV29Y2ylT8GBxovvHqZHePwMvddDmZxfPn-4fJeB4LTGkbp4hJqVOREFXmUFLEtRIsjAyxllKgpCw5ZlwjxjJJWJblkCuSExwqVZriEbjscxtn3zrl26KuvFCbMKmynS8QplmeozxN_k0JC_T8F13bzpnwkE-V0mBwUFe9Es5675QuGlfV3G0LBIuPFRQ_VxD42S60K2slv_HXnwdw0YO69oVR6_rvnHe8bIrL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1367564933</pqid></control><display><type>article</type><title>Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Jenkins, Ian ; Humber, Doug ; Bhatt, Vijaya R ; Aryal, Madan R ; Armitage, James O</creator><creatorcontrib>Jenkins, Ian ; Humber, Doug ; Bhatt, Vijaya R ; Aryal, Madan R ; Armitage, James O</creatorcontrib><description>To the Editor:
Kelton et al. (Feb. 21 issue)
1
recommend fondaparinux for the management of heparin-induced thrombocytopenia in patients with normal renal function because of its ease of use and familiarity, but it has another advantage as well: cost. At our institution, 10 days of treatment with fondaparinux at a dose of 7.5 mg per day costs $400. A 10-day infusion of argatroban costs approximately $7,440, plus an estimated $800 in laboratory costs and the indirect cost of pharmacist supervision, which in sum costs at least $7,840 more than fondaparinux. The costs of different treatment options are particularly relevant when . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc1303640</identifier><identifier>PMID: 23758251</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Anticoagulants ; Anticoagulants - therapeutic use ; Antithrombins - therapeutic use ; Catheters ; Costs ; Familiarity ; Heparin ; Heparin, Low-Molecular-Weight - adverse effects ; Humans ; Male ; Renal function ; Side effects ; Thrombocytopenia ; Thrombocytopenia - drug therapy</subject><ispartof>The New England journal of medicine, 2013-06, Vol.368 (24), p.2333-2334</ispartof><rights>Copyright © 2013 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-519ddf5c24eb80d61afec903603fddc12bba39af1997d497780ae4843ae46ef63</citedby><cites>FETCH-LOGICAL-c366t-519ddf5c24eb80d61afec903603fddc12bba39af1997d497780ae4843ae46ef63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc1303640$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1367564933?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23758251$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jenkins, Ian</creatorcontrib><creatorcontrib>Humber, Doug</creatorcontrib><creatorcontrib>Bhatt, Vijaya R</creatorcontrib><creatorcontrib>Aryal, Madan R</creatorcontrib><creatorcontrib>Armitage, James O</creatorcontrib><title>Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Kelton et al. (Feb. 21 issue)
1
recommend fondaparinux for the management of heparin-induced thrombocytopenia in patients with normal renal function because of its ease of use and familiarity, but it has another advantage as well: cost. At our institution, 10 days of treatment with fondaparinux at a dose of 7.5 mg per day costs $400. A 10-day infusion of argatroban costs approximately $7,440, plus an estimated $800 in laboratory costs and the indirect cost of pharmacist supervision, which in sum costs at least $7,840 more than fondaparinux. The costs of different treatment options are particularly relevant when . . .</description><subject>Anticoagulants</subject><subject>Anticoagulants - therapeutic use</subject><subject>Antithrombins - therapeutic use</subject><subject>Catheters</subject><subject>Costs</subject><subject>Familiarity</subject><subject>Heparin</subject><subject>Heparin, Low-Molecular-Weight - adverse effects</subject><subject>Humans</subject><subject>Male</subject><subject>Renal function</subject><subject>Side effects</subject><subject>Thrombocytopenia</subject><subject>Thrombocytopenia - drug therapy</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0T1PwzAQBmALgWgpbMwoEgwMBOzYceIFqaoKBZWylDly_EFTNXawk6H_HkMKQogBD-fhHr06-wA4RfAawZTeLKaPTwJhiCmBe2CIUoxjQiDdB0MIkzwmGcMDcOT9GoaDCDsEgwRnaZ6kaAhuF9asVMNdZaKxaSth-Wu34ab1kbYumvWt-MHITigZLVfO1qUV29Y2ylT8GBxovvHqZHePwMvddDmZxfPn-4fJeB4LTGkbp4hJqVOREFXmUFLEtRIsjAyxllKgpCw5ZlwjxjJJWJblkCuSExwqVZriEbjscxtn3zrl26KuvFCbMKmynS8QplmeozxN_k0JC_T8F13bzpnwkE-V0mBwUFe9Es5675QuGlfV3G0LBIuPFRQ_VxD42S60K2slv_HXnwdw0YO69oVR6_rvnHe8bIrL</recordid><startdate>20130613</startdate><enddate>20130613</enddate><creator>Jenkins, Ian</creator><creator>Humber, Doug</creator><creator>Bhatt, Vijaya R</creator><creator>Aryal, Madan R</creator><creator>Armitage, James O</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130613</creationdate><title>Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia</title><author>Jenkins, Ian ; Humber, Doug ; Bhatt, Vijaya R ; Aryal, Madan R ; Armitage, James O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-519ddf5c24eb80d61afec903603fddc12bba39af1997d497780ae4843ae46ef63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Anticoagulants</topic><topic>Anticoagulants - therapeutic use</topic><topic>Antithrombins - therapeutic use</topic><topic>Catheters</topic><topic>Costs</topic><topic>Familiarity</topic><topic>Heparin</topic><topic>Heparin, Low-Molecular-Weight - adverse effects</topic><topic>Humans</topic><topic>Male</topic><topic>Renal function</topic><topic>Side effects</topic><topic>Thrombocytopenia</topic><topic>Thrombocytopenia - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jenkins, Ian</creatorcontrib><creatorcontrib>Humber, Doug</creatorcontrib><creatorcontrib>Bhatt, Vijaya R</creatorcontrib><creatorcontrib>Aryal, Madan R</creatorcontrib><creatorcontrib>Armitage, James O</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jenkins, Ian</au><au>Humber, Doug</au><au>Bhatt, Vijaya R</au><au>Aryal, Madan R</au><au>Armitage, James O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2013-06-13</date><risdate>2013</risdate><volume>368</volume><issue>24</issue><spage>2333</spage><epage>2334</epage><pages>2333-2334</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Kelton et al. (Feb. 21 issue)
1
recommend fondaparinux for the management of heparin-induced thrombocytopenia in patients with normal renal function because of its ease of use and familiarity, but it has another advantage as well: cost. At our institution, 10 days of treatment with fondaparinux at a dose of 7.5 mg per day costs $400. A 10-day infusion of argatroban costs approximately $7,440, plus an estimated $800 in laboratory costs and the indirect cost of pharmacist supervision, which in sum costs at least $7,840 more than fondaparinux. The costs of different treatment options are particularly relevant when . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>23758251</pmid><doi>10.1056/NEJMc1303640</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2013-06, Vol.368 (24), p.2333-2334 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1367881852 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Anticoagulants Anticoagulants - therapeutic use Antithrombins - therapeutic use Catheters Costs Familiarity Heparin Heparin, Low-Molecular-Weight - adverse effects Humans Male Renal function Side effects Thrombocytopenia Thrombocytopenia - drug therapy |
| title | Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T22%3A34%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nonheparin%20Anticoagulants%20for%20Heparin-Induced%20Thrombocytopenia&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Jenkins,%20Ian&rft.date=2013-06-13&rft.volume=368&rft.issue=24&rft.spage=2333&rft.epage=2334&rft.pages=2333-2334&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc1303640&rft_dat=%3Cproquest_cross%3E1367881852%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1367564933&rft_id=info:pmid/23758251&rfr_iscdi=true |